TUXARIN ER (chlorpheniramine maleate)
TUXARIN ER is indicated for the treatment of Hay Fever; Allergic Rhinitis; Upper Respiratory Allergy.
Details
- Status
- Prescription
- First Approved
- 2015-06-22
- Patent Cliff
- 2032
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE
TUXARIN ER Approval History
What TUXARIN ER Treats
3 indicationsTUXARIN ER is approved for 3 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hay Fever
- Allergic Rhinitis
- Upper Respiratory Allergy
TUXARIN ER Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to TUXARIN ER
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TUXARIN ER FDA Label Details
Indications & Usage
FDA Label (PDF)TUXARIN ER is indicated for the treatment of Hay Fever; Allergic Rhinitis; Upper Respiratory Allergy.
Pro Intelligence Preview
Deep insights for TUXARIN ER
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2032
- • 2 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.